Medacta Group Reports Strong H1 2025 Performance with Revenue and EBITDA Growth
Medacta Group SA reported a strong first-half 2025 performance, with revenue rising 19.8% and adjusted EBITDA expanding 27.5% year-over-year, driven by growth in its orthopedic and neurosurgical devices business.
2 minutes to read